<DOC>
	<DOCNO>NCT01237808</DOCNO>
	<brief_summary>This randomize , Phase-III , two-arm , open-label , multi-center study adult patient AML NPM1 mutation ineligible intensive chemotherapy . Sample size : 144 patient Investigator 's site : 50-55 site Germany Austria ( 2-10 patient per trial site expect included trial ) Estimated treatment duration individual patient : 8 month ( Follow-Up period per patient last additional 2 year )</brief_summary>
	<brief_title>Study Low-Dose Cytarabine Etoposide With Without All-Trans Retinoic Acid Older Patients Not Eligible Intensive Chemotherapy With Acute Myeloid Leukemia NPM1 Mutation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Patients confirm diagnosis acute myeloid leukemia accord World Health Organization ( WHO ) classification ( include de novo AML , tAML sAML ) Presence NPM1 mutation assess one central AMLSG reference laboratory . Age &gt; 60 year . There upper age limit . No prior chemotherapy leukemia except hydroxyurea control hyperleukocytosis need 10 day diagnostic screening phase . Signed write informed consent Men must give informed consent father baby must use latex condom sexual contact woman childbearing potential , even undergone successful vasectomy . ( therapy 3 month last dose chemotherapy ) WHO performance status ≤ 3 Patients eligible intensive chemotherapy accord least one follow criterion HCTCI Score &gt; 2 Patient 's decision age ≥ 75 year The presence follow exclude patient study enrollment : All AML subtypes , particular AML recurrent genetic change ( accord WHO 2008 ) : AML ( 8 ; 21 ) ( q22 ; q22 ) ; RUNX1RUNX1T1 AML inv ( 16 ) ( p13.1q22 ) ( 16 ; 16 ) ( p13.1 ; q22 ) ; CBFBMYH11 AML ( 15 ; 17 ) ( q22 ; q12 ) ; PMLRARA ( translocation involve RARA ) AML ( 9 ; 11 ) ( p22 ; q23 ) ; MLLT3MLL ( translocation involve MLL ) AML ( 6 ; 9 ) ( p23 ; q34 ) ; DEKNUP214 AML inv ( 3 ) ( q21q26.2 ) ( 3 ; 3 ) ( q21 ; q26.2 ) ; RPN1EVI1 No consent registration , storage process individual diseasecharacteristics course well information family physician treat physician study participation Bleeding disorder independent leukemia Uncontrolled infection Known positive HIV , HBV HCV Organ insufficiency ( creatinine &gt; 1.5x upper normal serum level ; bilirubin , AST ALP &gt; 2.5x upper normal serum level , attributable AML ; heart failure NYHA III/IV ; severe obstructive restrictive ventilation disorder ) Severe neurological psychiatric disorder interfere ability give informed consent Patients `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse within one year .</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>NPM1 Mutation</keyword>
	<keyword>elderly patient ( &gt; 60 year )</keyword>
	<keyword>unfit intensive chemotherapy</keyword>
</DOC>